172 related articles for article (PubMed ID: 15715660)
21. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease.
Ebadi M; Sharma SK
Antioxid Redox Signal; 2003 Jun; 5(3):319-35. PubMed ID: 12880486
[TBL] [Abstract][Full Text] [Related]
22. Synergistic inhibition of respiration in brain mitochondria by nitric oxide and dihydroxyphenylacetic acid (DOPAC). Implications for Parkinson's disease.
Nunes C; Almeida L; Laranjinha J
Neurochem Int; 2005 Aug; 47(3):173-82. PubMed ID: 15893407
[TBL] [Abstract][Full Text] [Related]
23. Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo.
Kim HW; Choi WS; Sorscher N; Park HJ; Tronche F; Palmiter RD; Xia Z
Neurobiol Aging; 2015 Sep; 36(9):2617-27. PubMed ID: 26070241
[TBL] [Abstract][Full Text] [Related]
24. A disruption in iron-sulfur center biogenesis via inhibition of mitochondrial dithiol glutaredoxin 2 may contribute to mitochondrial and cellular iron dysregulation in mammalian glutathione-depleted dopaminergic cells: implications for Parkinson's disease.
Lee DW; Kaur D; Chinta SJ; Rajagopalan S; Andersen JK
Antioxid Redox Signal; 2009 Sep; 11(9):2083-94. PubMed ID: 19290777
[TBL] [Abstract][Full Text] [Related]
25. Reversible inactivation of alpha-ketoglutarate dehydrogenase in response to alterations in the mitochondrial glutathione status.
Nulton-Persson AC; Starke DW; Mieyal JJ; Szweda LI
Biochemistry; 2003 Apr; 42(14):4235-42. PubMed ID: 12680778
[TBL] [Abstract][Full Text] [Related]
26. Bioenergetic and oxidative effects of free 3-nitrotyrosine in culture: selective vulnerability of dopaminergic neurons and increased sensitivity of non-dopaminergic neurons to dopamine oxidation.
Ma TC; Mihm MJ; Bauer JA; Hoyt KR
J Neurochem; 2007 Oct; 103(1):131-44. PubMed ID: 17877636
[TBL] [Abstract][Full Text] [Related]
27. Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxyli c acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's disease.
Li H; Dryhurst G
J Neurochem; 1997 Oct; 69(4):1530-41. PubMed ID: 9326282
[TBL] [Abstract][Full Text] [Related]
28. TNF-α regulates miRNA targeting mitochondrial complex-I and induces cell death in dopaminergic cells.
Prajapati P; Sripada L; Singh K; Bhatelia K; Singh R; Singh R
Biochim Biophys Acta; 2015 Mar; 1852(3):451-61. PubMed ID: 25481834
[TBL] [Abstract][Full Text] [Related]
29. Treatment with 1,2,3,4-tetrahydroisoquinolone affects the levels of nitric oxide, S-nitrosothiols, glutathione and the enzymatic activity of gamma-glutamyl transpeptidase in the dopaminergic structures of rat brain.
Lorenc-Koci E; Sokołowska M; Kwiecień I; Włodek L
Brain Res; 2005 Jul; 1049(2):133-46. PubMed ID: 15946655
[TBL] [Abstract][Full Text] [Related]
30. Pre-treatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications for Parkinson's disease therapy.
Bharat S; Cochran BC; Hsu M; Liu J; Ames BN; Andersen JK
Neurotoxicology; 2002 Oct; 23(4-5):479-86. PubMed ID: 12428720
[TBL] [Abstract][Full Text] [Related]
31. Characterization of the role of glutathione in repin-induced mitochondrial dysfunction, oxidative stress and dopaminergic neurotoxicity in rat pheochromocytoma (PC12) cells.
Tukov FF; Rimoldi JM; Matthews JC
Neurotoxicology; 2004 Dec; 25(6):989-99. PubMed ID: 15474617
[TBL] [Abstract][Full Text] [Related]
32. Mitochondrial damage by nitric oxide is potentiated by dopamine in PC12 cells.
Antunes F; Han D; Rettori D; Cadenas E
Biochim Biophys Acta; 2002 Dec; 1556(2-3):233-8. PubMed ID: 12460681
[TBL] [Abstract][Full Text] [Related]
33. Novel imine antioxidants at low nanomolar concentrations protect dopaminergic cells from oxidative neurotoxicity.
Hajieva P; Mocko JB; Moosmann B; Behl C
J Neurochem; 2009 Jul; 110(1):118-32. PubMed ID: 19486265
[TBL] [Abstract][Full Text] [Related]
34. Glutathione, iron and Parkinson's disease.
Bharath S; Hsu M; Kaur D; Rajagopalan S; Andersen JK
Biochem Pharmacol; 2002 Sep; 64(5-6):1037-48. PubMed ID: 12213603
[TBL] [Abstract][Full Text] [Related]
35. Oxidative metabolites of 5-S-cysteinylnorepinephrine are irreversible inhibitors of mitochondrial complex I and the alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase complexes: possible implications for neurodegenerative brain disorders.
Xin W; Shen XM; Li H; Dryhurst G
Chem Res Toxicol; 2000 Aug; 13(8):749-60. PubMed ID: 10956063
[TBL] [Abstract][Full Text] [Related]
36. Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons.
Kikuchi S; Shinpo K; Tsuji S; Takeuchi M; Yamagishi S; Makita Z; Niino M; Yabe I; Tashiro K
Brain Res; 2003 Feb; 964(2):228-36. PubMed ID: 12576183
[TBL] [Abstract][Full Text] [Related]
37. Mitochondrial glutathione protects against cell death induced by oxidative and nitrative stress in astrocytes.
Muyderman H; Wadey AL; Nilsson M; Sims NR
J Neurochem; 2007 Aug; 102(4):1369-82. PubMed ID: 17484727
[TBL] [Abstract][Full Text] [Related]
38. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxyli c acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson's disease.
Li H; Shen XM; Dryhurst G
J Neurochem; 1998 Nov; 71(5):2049-62. PubMed ID: 9798930
[TBL] [Abstract][Full Text] [Related]
39. Mitochondrial respiration and respiration-associated proteins in cell lines created through Parkinson's subject mitochondrial transfer.
Esteves AR; Lu J; Rodova M; Onyango I; Lezi E; Dubinsky R; Lyons KE; Pahwa R; Burns JM; Cardoso SM; Swerdlow RH
J Neurochem; 2010 May; 113(3):674-82. PubMed ID: 20132468
[TBL] [Abstract][Full Text] [Related]
40. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
